Patents by Inventor Felix Herth

Felix Herth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses
    Patent number: 11402381
    Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 2, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Friedemann Krause, Vinzent Rolny, Farshid Dayyani, Achim Escherich, Birgit Wehnl, Ying He, Julia Riedlinger, Felix Herth, Thomas Muley
  • METHOD OF CANCER PROGNOSIS BY ASSESSING TUMOR VARIANT DIVERSITY
    Publication number: 20210222251
    Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising measuring tumor genetic heterogeneity via analysis of circulating tumor DNA from a patient's sample.
    Type: Application
    Filed: May 8, 2019
    Publication date: July 22, 2021
    Applicant: Roche Sequencing Solutions, Inc.
    Inventors: Aarthi BALASUBRAMANYAM, Felix HERTH, Christine JU, Xiaoju MA, Thomas MULEY, Birgit WEHNL, Liu XI, Stephanie J. YAUNG
  • SURROGATE MARKER AND METHOD FOR TUMOR MUTATION BURDEN MEASUREMENT
    Publication number: 20210054465
    Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 25, 2021
    Inventors: Aarthi Balasubramanyam, Christine Ju, Xiaoju Ma, Thomas Muley, Felix Herth, Nalin Tikoo, Birgit Wehnl, Liu Xi, Stephanie J. Yaung, Amrita Pati
  • METHOD OF PREDICTING RESPONSE TO THERAPY BY ASSESSING TUMOR GENETIC HETEROGENEITY
    Publication number: 20200399711
    Abstract: The invention is a method of predicting response to therapy in a cancer patient by serial sampling the patient's cell-free tumor nucleic acids to determine a change in the number of mutations per amount of plasma.
    Type: Application
    Filed: February 11, 2019
    Publication date: December 24, 2020
    Inventors: Aarthi Balasubramanyam, Christine Ju, Xiaoju Ma, Thomas Muley, Felix Herth, Nalin Tikoo, Birgit Wehnl, Liu Xi, Stephanie J. Yaung
  • METHODS OF DETECTING A RELAPSE OF A LUNG ADENOCARCINOMA BASED ON MARKER HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AND RELATED USES
    Publication number: 20180292410
    Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Farshid Dayyani, Friedemann Krause, Achim Escherich, Birgit Wehnl, Ying He, Vinzent Rolny, Sandra Rutz, Thomas Muley, Felix Herth, Julia Riedlinger
  • METHODS OF IDENTIFYING AN INDIVIDUAL TO BE TREATED BY CHEMOTHERAPY BASED ON MARKER MOLECULES AND RELATED USES
    Publication number: 20180231557
    Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 16, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Friedemann Krause, Vinzent Rolny, Farshid Dayyani, Achim Escherich, Birgit Wehnl, Ying He, Julia Riedlinger, Felix Herth, Thomas Muley